We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | 장 마감 후 (AMC) | $-0.08 | — | — | $49.2M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.15 | — | — | $16.52M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-0.53 | — | — | $7.19M |
Consensus PT $13 · 3 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 21. | BTIG | — | 의견 유지 | Buy → Buy | — | BTIG: Buy |
| 2026. 05. 20. | HC Wainwright & Co. | — | 의견 유지 | Buy → Buy | — | HC Wainwright & Co.: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.4 | — | — | $1.09M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 4,385,500 | $33.64B | 0.03% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 4,717,843 | $9.34B | 0.01% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Stored first · Google News · Yahoo Finance (English)
IBRX and the BCG Shortage: Deals That Could Expand Demand - Yahoo Finance
IBRX and the BCG Shortage: Deals That Could Expand Demand Yahoo Finance
IBRX Stock Outlook After Q1 Results and a New FDA Review - Yahoo Finance
IBRX Stock Outlook After Q1 Results and a New FDA Review Yahoo Finance
ImmunityBio: Anktiva Explained and What Comes Next - Yahoo Finance
ImmunityBio: Anktiva Explained and What Comes Next Yahoo Finance
ImmunityBio (IBRX) Health Economic Analysis Highlights ANKTIVA Value Over TAR-200 - Yahoo Finance
ImmunityBio (IBRX) Health Economic Analysis Highlights ANKTIVA Value Over TAR-200 Yahoo Finance
ANKTIVA Label Expansion Bid in Papillary NMIBC Could Be A Game Changer For ImmunityBio (IBRX) - Yahoo Finance
ANKTIVA Label Expansion Bid in Papillary NMIBC Could Be A Game Changer For ImmunityBio (IBRX) Yahoo Finance